The effect of mRNA-lipid nanoparticle composition on stability during microneedle patch manufacturing
Messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) is a potent technology with broad applications. Microneedle patches (MNPs) can enhance the accessibility of mRNA-LNPs for vaccination or therapeutic applications. We evaluated the effects of LNP composition on the stability of mRNA-LNPs before and after MNP manufacturing, as assessed by changes in mRNA-LNP size, encapsulation efficiency, and protein expression in vitro and in vivo. The lipid molar ratio had a significant impact on LNP characteristics and ability to withstand stressors of MNP fabrication. An elevation in ionizable lipid content from 50% to 60% increased in vitro mRNA expression, measured by luciferase expression in RAW 264.7 cells, following extraction from an MNP. Among the three ionizable lipids tested, SM-102 had the highest expression before and after MNP manufacturing. Cholesterol analogues influenced in vivo expression of mRNA-LNPs before MNP manufacturing, but the effect was absent in mRNA-LNP MNPs. PEGylated lipid choice affected mRNA encapsulation in LNPs and had a strong effect on in vitro expression, but this effect was not seen in vivo. Phospholipid choice did not have a significant impact on most mRNA-LNP characteristics, but the use of DOTMA increased in vitro expression. These data suggest that LNP composition can affect mRNA-LNP characteristics and function both before and after MNP manufacturing. Future mRNA-LNP MNP designs should consider the effect of lipid molar ratios and favor higher ionizable lipid content.
Authors
- Mark R. Prausnitz (ORCID: https://orcid.org/0000-0002-9076-8448)
- B. Pradeep K. Reddy (ORCID: https://orcid.org/0000-0002-0696-1721)
- James E. Dahlman (ORCID: https://orcid.org/0000-0001-7580-436X)
- Katherine Byrne
- Sophia H Sakers
- Gianna Fiduccia
Institutions
- Georgia Institute of Technology (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- European Journal of Pharmaceutics and Biopharmaceutics
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1016/j.ejpb.2025.114819
- Citations
- 1
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.79
Funders
- Bill and Melinda Gates Foundation